Sheryl Gruen, MD
Family Medicine · Lampasas, TXNPI 1740262377
Payments from drug & device makers
Across 288 payments — averaging $16.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$563
- Novo Nordisk$562
- Pfizer$468
- GSK$386
- AstraZeneca$368
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$332
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,633100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 37 | $563 |
| Novo Nordisk | 33 | $562 |
| Pfizer | 27 | $468 |
| GSK | 27 | $386 |
| AstraZeneca | 25 | $368 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $332 |
| Lilly USA, LLC | 13 | $200 |
| Dexcom, Inc. | 12 | $187 |
| Amgen | 11 | $164 |
| Biohaven Pharmaceuticals, Inc. | 4 | $146 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $123 |
| Boehringer Ingelheim | 6 | $112 |
| Sumitomo Pharma America, Inc. | 4 | $107 |
| Sunovion Pharmaceuticals Inc. | 6 | $99 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $92 |
| Abbott | 4 | $86 |
| Novartis | 5 | $82 |
| Sanofi-aventis U.S. LLC | 4 | $60 |
| Merck | 4 | $57 |
| Corium, LLC | 2 | $49 |
| Cranial Technologies, Inc | 3 | $48 |
| Biogen | 3 | $46 |
| E.r. Squibb & Sons, L.L.C. | 3 | $44 |
| Corcept Therapeutics | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $31 |
| Astellas Pharma US Inc | 2 | $25 |
| Johnson & Johnson | 2 | $24 |
| Averitas Pharma Inc. | 1 | $22 |
| Antares Pharma, Inc. | 1 | $19 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Exact Sciences | 1 | $15 |
| Valeritas, Inc. | 1 | $14 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Circassia Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$4,651 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 186 | $203,824 |
| JardianceEmpagliflozin | 191 | $174,002 |
| OzempicSemaglutide | 75 | $98,316 |
| TrulicityDulaglutide | 54 | $73,990 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $69,195 |
| EliquisApixaban | 95 | $60,240 |
| XifaxanRifaximin | 12 | $45,492 |
| JanuviaSitagliptin Phosphate | 62 | $43,341 |
| XareltoRivaroxaban | 65 | $38,901 |
| MyrbetriqMirabegron | 82 | $34,017 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $32,181 |
| ProliaDenosumab | 17 | $28,592 |
| FarxigaDapagliflozin Propanediol | 30 | $25,004 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $20,291 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $17,033 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $200 | $277,814240 claims |
| Boehringer IngelheimJardiance | $112 | $174,002191 claims |
| Novo NordiskOzempic | $562 | $98,31675 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $386 | $79,749116 claims |
| PfizerEliquis | $468 | $60,24095 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $368 | $53,97782 claims |
| MerckJanuvia, Belsomra | $57 | $48,77974 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $332 | $45,49212 claims |
| Johnson & JohnsonXarelto | $24 | $38,90165 claims |
| Astellas Pharma US IncMyrbetriq | $25 | $34,01782 claims |
| AmgenProlia | $164 | $28,59217 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $123 | $12,47728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Lampasas
- Vanna GoldLampasas$3.3M
- James CainLampasas$2.9M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.